PURPOSE: We assessed clinical outcome and long-term tumor control after fractionated stereotactic radiotherapy (FSRT) for unilateral schwannoma. METHODS AND MATERIALS: Between 1995 and 2007, 496 patients were treated with fractionated stereotactic radiotherapy at Johns Hopkins Hospital (Baltimore, MD); 385 patients had radiologic follow-up that met the inclusion criteria. The primary endpoint was treatment failure. Secondary endpoints were radiologic progression and clinical outcome. Logistic regression analysis assessed the association of age, race, tumor side, sex, and pretreatment symptoms. RESULTS: In 11 patients (3%) treatment failed, and they required salvage (microsurgical) treatment. Radiologic progression was observed in 116 patients (30.0%), including 35 patients (9%) in whom the treatment volume more than doubled during the follow-up period, although none required surgical resection. Tumors with baseline volumes of less than 1 cm(3) were 18.02 times more likely to progress than those with tumor volumes of 1 cm(3) or greater (odds ratio, 18.02; 95% confidence interval, 4.25-76.32). Treatment-induced neurologic morbidity included 8 patients (1.6%) with new facial weakness, 12 patients (2.8%) with new trigeminal paresthesias, 4 patients (0.9%) with hydrocephalus (1 communicating and 3 obstructive), and 2 patients (0.5%) with possibly radiation-induced neoplasia. CONCLUSIONS: Although the rate of treatment failure is low (3%), careful follow-up shows that radiologic progression occurs frequently. When reporting outcome, the "no salvage surgery needed" and "no additional treatment needed" criteria for treatment success need to be complemented by the radiologic data.
PURPOSE: We assessed clinical outcome and long-term tumor control after fractionated stereotactic radiotherapy (FSRT) for unilateral schwannoma. METHODS AND MATERIALS: Between 1995 and 2007, 496 patients were treated with fractionated stereotactic radiotherapy at Johns Hopkins Hospital (Baltimore, MD); 385 patients had radiologic follow-up that met the inclusion criteria. The primary endpoint was treatment failure. Secondary endpoints were radiologic progression and clinical outcome. Logistic regression analysis assessed the association of age, race, tumor side, sex, and pretreatment symptoms. RESULTS: In 11 patients (3%) treatment failed, and they required salvage (microsurgical) treatment. Radiologic progression was observed in 116 patients (30.0%), including 35 patients (9%) in whom the treatment volume more than doubled during the follow-up period, although none required surgical resection. Tumors with baseline volumes of less than 1 cm(3) were 18.02 times more likely to progress than those with tumor volumes of 1 cm(3) or greater (odds ratio, 18.02; 95% confidence interval, 4.25-76.32). Treatment-induced neurologic morbidity included 8 patients (1.6%) with new facial weakness, 12 patients (2.8%) with new trigeminal paresthesias, 4 patients (0.9%) with hydrocephalus (1 communicating and 3 obstructive), and 2 patients (0.5%) with possibly radiation-induced neoplasia. CONCLUSIONS: Although the rate of treatment failure is low (3%), careful follow-up shows that radiologic progression occurs frequently. When reporting outcome, the "no salvage surgery needed" and "no additional treatment needed" criteria for treatment success need to be complemented by the radiologic data.
Authors: H G Deen; M J Ebersold; S G Harner; C W Beatty; M S Marion; R E Wharen; J D Green; L Quast Journal: Neurosurgery Date: 1996-08 Impact factor: 4.654
Authors: William M Mendenhall; William A Friedman; Robert J Amdur; Patrick J Antonelli Journal: Am J Otolaryngol Date: 2004 Jan-Feb Impact factor: 1.808
Authors: T Schneider; J Chapiro; M Lin; J F Geschwind; L Kleinberg; D Rigamonti; I Jusué-Torres; A E Marciscano; D M Yousem Journal: Eur Radiol Date: 2015-07-03 Impact factor: 5.315
Authors: Debnarayan Dutta; S Balaji Subramanian; V Murli; H Sudahar; P G Gopalakrishna Kurup; Mahadev Potharaju Journal: J Neurooncol Date: 2011-09-04 Impact factor: 4.130
Authors: Anurag Saraf; Luke R G Pike; Kevin H Franck; Nora K Horick; Beow Y Yeap; Barbara C Fullerton; Irene S Wang; Mohamed E Abazeed; Michael J McKenna; William A Mehan; Scott R Plotkin; Jay S Loeffler; Helen A Shih Journal: Neurosurgery Date: 2022-05-01 Impact factor: 5.315
Authors: Scott G Soltys; Michael T Milano; Jinyu Xue; Wolfgang A Tomé; Ellen Yorke; Jason Sheehan; George X Ding; John P Kirkpatrick; Lijun Ma; Arjun Sahgal; Timothy Solberg; John Adler; Jimm Grimm; Issam El Naqa Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-26 Impact factor: 8.013
Authors: Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna Journal: Neurooncol Pract Date: 2021-02-01